Michiana Eye Center Llc in South Bend, IN - Medicare Ophthalmology Provider

Michiana Eye Center Llc is a medicare enrolled "Ophthalmology" provider in South Bend, Indiana. Their current practice location is 319 N Niles Ave # 100, South Bend, Indiana. You can reach out to their office (for appointments etc.) via phone at (574) 282-2020.

Michiana Eye Center Llc is licensed to practice in * (Not Available) (license number ) and it also participates in the medicare program. Michiana Eye Center Llc is enrolled with medicare and should accept medicare assignments and since they are enrolled in medicare, they may order Medicare Part D Prescription drugs, if eligible. The facility's NPI Number is 1073671731.

Contact Information

	Michiana Eye Center Llc
	319 N Niles Ave # 100, South Bend, IN 46617
	(574) 282-2020
	(574) 288-2020

Healthcare Provider's Profile

Full Name	Michiana Eye Center Llc
Type	Facility
Speciality	Ophthalmology
Location	319 N Niles Ave # 100, South Bend, Indiana
Accepts Medicare Assignments	Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs.

NPI Data:

NPI Number: 1073671731
Provider Enumeration Date: 12/05/2006
Last Update Date: 06/18/2018

Medicare PECOS Information:

PECOS PAC ID: 3173595634
Enrollment ID: O20100930009052

Medical Identifiers

Medical identifiers for Michiana Eye Center Llc such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1073671731	NPI	-	NPPES
204460	Other	IN	MEDICARE PTAN
100092980	Medicaid	IN
DA1131	Other	IN	RAILROAD MEDICARE

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
152W00000X	Optometrist	(* (Not Available))	Secondary
174400000X	Specialist	(* (Not Available))	Secondary
207W00000X	Ophthalmology	(* (Not Available))	Primary
2082S0099X	Plastic Surgery - Plastic Surgery Within The Head And Neck	(* (Not Available))	Secondary
332B00000X	Durable Medical Equipment & Medical Supplies	(* (Not Available))	Secondary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Michiana Eye Center Llc is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Michiana Eye Center Llc 230 E Day Rd Ste 100, Mishawaka, IN 46545-3408 Ph: (574) 271-3939	Michiana Eye Center Llc 319 N Niles Ave # 100, South Bend, IN 46617 Ph: (574) 282-2020

News Archive

Studies shed light on propensity for habit formation in obsessive-compulsive disorder

Two new studies published this week in Biological Psychiatry shed light on the propensity for habit formation in obsessive-compulsive disorder (OCD). These studies suggest that a tendency to develop habits, i.e., the compulsive component of the disorder, may be a core feature of the disorder rather than a consequence of irrational beliefs.

U.N. progress report on AIDS stresses advances in treatment, prevention, warns about declining funding

"Global progress in both preventing and treating HIV emphasizes the benefits of sustaining investment in HIV/AIDS over the longer term," according to a new report from the WHO, UNICEF and UNAIDS, which also "indicates that increased access to HIV services resulted in a 15 percent reduction of new infections over the past decade and a 22 percent decline in AIDS-related deaths in the last five years," a WHO press release reports.

Opexa Therapeutics' endeavor in the field of stem cell technology

Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing Tovaxin®, a personalized T-cell immunotherapy for multiple sclerosis (MS), today announced that it has achieved its first technology transfer milestone in connection with the company's recently announced exclusive stem cell agreement with Novartis, one of the world's largest healthcare companies. The milestone was completed on schedule and triggers a payment of $500,000 to Opexa.

Cardiovascular and Renal Drugs Advisory Committee recommends FDA approval of J&JPRD's rivaroxaban

Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD) announced today that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee recommended approval of rivaroxaban, a novel, once-daily, oral anticoagulant, for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.

Michiana Eye Center Llc - Medicare in South Bend, IN